1. Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. First-Line Treatment Algorithm in Advanced NSCLC

6. Immunotherapies Approved for Second-Line Treatment

7. Meta-Analysis of Second-Line Immunotherapy Trials Regarding EGFR Mutation Status

8. PD-1 vs PD-L1 Directed Therapy in the EGFR+ Population

9. Stage III NSCLC Consolidation Therapy: PACIFIC

10. Who Benefits From Immunotherapy?

11. TMB as a Biomarker

12. Assessment of TMB in CheckMate 026

13. TMB and Neoantigens

14. Biomarkers in EGFR+ NSCLC

15. Types of Tumor Microenvironments Driving PD-L1 Expression

16. PD-L1 and TILs in EGFR+ NSCLC

17. Third-Line and Further Immunotherapy From ATLANTIC

18. Safety Concerns With Immunotherapy

19. Safety Concerns: Combinations

20. Consequences of Immunotherapy Toxicity

21. CheckMate 012: Nivolumab Plus Ipilimumab

22. MYSTIC: Durvalumab in Monotherapy and Combination

23. IMpower150: Atezolizumab Combination

24. Why Is IMpower150 Different From Prior EGFR+ Trials?

25. Examples of Other Ongoing Studies in EGFR+ NSCLC

26. Concluding Remarks

27. Abbreviations

28. Abbreviations (cont)